DISCOUNT OPTIONSSCHEIN - ELI LILLY & CO | Real-time Bid/Ask 12:23:17 2024-06-10 pm EDT | ||
| 1.71 EUR / 1.78 EUR | +12.58% |
|
| Current month | +32.48% | ||
| 1 month | +66.67% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-06-10 | 1.66 | +7.10% |
| 24-06-07 | 1.55 | +16.54% |
| 24-06-06 | 1.33 | -1.48% |
| 24-06-05 | 1.35 | +0.75% |
| 24-06-04 | 1.34 | -4.29% |
Delayed Quote Börse Stuttgart
Last update June 10, 2024 at 08:16 am EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | Morgan Stanley |
| WKN | ME903T |
| ISIN | DE000ME903T6 |
| Date issued | 2024-02-20 |
| Strike | 950 $ |
| Maturity | 2024-09-20 (102 Days) |
| Parity | 10 : 1 |
| Emission price | 1.29 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.71 € |
|---|---|
| Lowest since issue | 0.66 € |
| Spread | 0.04 € |
| Spread % | 2.30% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
850
USD
Average target price
853.8
USD
Spread / Average Target
+0.44%
- Stock Market
- Certificates
- Certificat
